HROW:NASDAQ
Harrow Inc
25,92 $
arrow_downward
-0,46%(-0,12) 1 T
6. Nov., 12:00:11 GMT-5 · USD
search
Alle Symbole
| Symbol | Kurs | Änderung | Änderung in % |
|---|
insights_autoWichtige Einblicke für HROW werden generiert…
Öffnen
26,40 $
Höchstwert
26,64 $
Tiefstwert
25,76 $
Börsenwert
971,68 Mio.
Durchschn. HVol.
600.249,00
Handelsvolumen
168.227,00
52-Wochen-Hoch
54,85 $
52-Wochen-Tief
25,76 $
EPS
-1,00 $
Beta
0,18
Aktien im Umlauf
37,49 Mio.
Anzahl der Mitarbeiter
373
Öffnen
26,40 $
Höchstwert
26,64 $
Tiefstwert
25,76 $
Börsenwert
971,68 Mio.
Durchschn. HVol.
600.249,00
Handelsvolumen
168.227,00
52-Wochen-Hoch
54,85 $
52-Wochen-Tief
25,76 $
EPS
-1,00 $
Beta
0,18
Aktien im Umlauf
37,49 Mio.
Anzahl der Mitarbeiter
373
Nachrichtenmeldungen
Aus Webquellen und von Nachrichtenpartnern
Zacks
·
vor 16 Stunden
Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates
Investing.com
·
vor 23 Stunden
Harrow stock hits 52-week low at 26.9 USD
Profil
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
Über Harrow Inc
CEOMark L. Baum Esq.
Mitarbeiter373
Gründungsdatum2012
HauptsitzNashville, Tennessee, USA
SektorHealth Care
Industry-
Websiteharrow.com